SCHEMBL5310029

SCHEMBL5310029

O=C(O)NCC1Cc2cccnc2N(Cc2ccc(F)cc2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
RIPK1 Q13546 10/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CNR1 P21554 2/20 0.36
CNR2 P34972 2/20 0.36
CHRM1 P11229 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886170 0.81 CYP1A2 (0.38) CYP1A2CYP2C19RIPK1KMT2AMEN1
SCHEMBL4894831 0.78 CYP1A2 (0.47) CYP1A2CYP2C19RIPK1KMT2AMEN1
SCHEMBL5310034 0.78 CYP1A2 (0.41) CYP1A2CYP2C19RIPK1KMT2AMEN1
SCHEMBL4886164 0.77 MEN1 (0.39) CYP1A2CYP2C19RIPK1KMT2AMEN1
Hydrochloric Acid SCHEMBL4897081 0.77 CYP1A2 (0.44) CYP1A2CYP2C19RIPK1KMT2AMEN1
SCHEMBL5315126 0.76 CYP1A2 (0.41) CYP1A2CYP2C19RIPK1KMT2AMEN1
SCHEMBL4897407 0.76 CYP1A2 (0.39) CYP1A2CYP2C19RIPK1KMT2AMEN1
SCHEMBL14280805 0.75 SCN9A (0.42) CYP1A2CYP2C19RIPK1KMT2ACNR1
SCHEMBL8274287 0.74 RIPK1 (0.41) CYP1A2CYP2C19RIPK1CNR1CNR2
SCHEMBL4894681 0.69 RIPK1 (0.37) CYP1A2CYP2C19RIPK1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758863-A1 TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES AstraZeneca AB (SE) 2007-03-07 EP disclosed
WO-2005123685-A1 TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES ASTRAZENECA AB (SE) 2005-12-29 WO disclosed